Mari Ariyasu

2.0k total citations · 3 hit papers
26 papers, 1.5k citations indexed

About

Mari Ariyasu is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, Mari Ariyasu has authored 26 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pharmacology, 15 papers in Molecular Medicine and 10 papers in Epidemiology. Recurrent topics in Mari Ariyasu's work include Antibiotics Pharmacokinetics and Efficacy (17 papers), Antibiotic Resistance in Bacteria (15 papers) and SARS-CoV-2 and COVID-19 Research (7 papers). Mari Ariyasu is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (17 papers), Antibiotic Resistance in Bacteria (15 papers) and SARS-CoV-2 and COVID-19 Research (7 papers). Mari Ariyasu collaborates with scholars based in Japan, United States and United Kingdom. Mari Ariyasu's co-authors include Tsutae Den Nagata, Roger Echols, Simon Portsmouth, Yuko Matsunaga, Richard G. Wunderink, Juan Camilo Arjona Ferreira, Mitsuaki Machida, David van Veenhuyzen, Matteo Bassetti and Kiichiro Toyoizumi and has published in prestigious journals such as Clinical Infectious Diseases, Scientific Reports and The Lancet Infectious Diseases.

In The Last Decade

Mari Ariyasu

25 papers receiving 1.5k citations

Hit Papers

Efficacy and safety of cefiderocol or best available ther... 2018 2026 2020 2023 2020 2020 2018 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
    2020 540 citations Matteo Bassetti, Roger Echols et al. The Lancet Infectious Diseases profile →
  2. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
    2020 319 citations Richard G. Wunderink, Yuko Matsunaga et al. The Lancet Infectious Diseases profile →
  3. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
    2018 305 citations Simon Portsmouth, David van Veenhuyzen et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mari Ariyasu Japan 11 1.2k 873 561 428 183 26 1.5k
Tsutae Den Nagata Japan 13 1.3k 1.0× 903 1.0× 584 1.0× 529 1.2× 188 1.0× 28 1.7k
Andrew Denisuik Canada 11 1.2k 1.0× 704 0.8× 349 0.6× 515 1.2× 215 1.2× 19 1.4k
Flora Kontopidou Greece 16 1.2k 1.0× 759 0.9× 347 0.6× 558 1.3× 235 1.3× 29 1.6k
Eric Wenzler United States 24 872 0.7× 636 0.7× 393 0.7× 444 1.0× 284 1.6× 80 1.5k
Giusy Tiseo Italy 22 890 0.7× 539 0.6× 483 0.9× 533 1.2× 165 0.9× 62 1.6k
Evangelos Papadomichelakis Greece 19 1.2k 1.0× 829 0.9× 261 0.5× 766 1.8× 224 1.2× 24 1.7k
Anthony Harris United States 14 1.1k 0.9× 439 0.5× 511 0.9× 467 1.1× 303 1.7× 24 1.5k
Sofia K. Kasiakou Greece 14 888 0.7× 645 0.7× 225 0.4× 560 1.3× 119 0.7× 16 1.4k
Francesca Ginocchio Italy 10 789 0.7× 446 0.5× 257 0.5× 320 0.7× 171 0.9× 14 1.1k
Noriel Mariano United States 19 780 0.6× 440 0.5× 220 0.4× 401 0.9× 209 1.1× 31 1.1k

Countries citing papers authored by Mari Ariyasu

Since Specialization
Citations

This map shows the geographic impact of Mari Ariyasu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mari Ariyasu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mari Ariyasu more than expected).

Fields of papers citing papers by Mari Ariyasu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mari Ariyasu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mari Ariyasu. The network helps show where Mari Ariyasu may publish in the future.

Co-authorship network of co-authors of Mari Ariyasu

This figure shows the co-authorship network connecting the top 25 collaborators of Mari Ariyasu. A scholar is included among the top collaborators of Mari Ariyasu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mari Ariyasu. Mari Ariyasu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thiểm, Vũ Đình, Hung Thai, Andrew J. Pollard, et al.. (2024). A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial. Vaccine. 42(17). 3699–3709. 1 indexed citations
2.
Yamano, Yoshinori, et al.. (2024). Cefiderocol: a first and novel class of siderophore cephalosporin for Carbapenem-resistant Gram-negative infection. Folia Pharmacologica Japonica. 159(5). 331–340.
3.
4.
Iwata, Satoshi, Andrew J. Pollard, Yukio Tada, et al.. (2024). A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults. Scientific Reports. 14(1). 9830–9830. 2 indexed citations
5.
Sonoyama, Takuhiro, et al.. (2023). Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan. Vaccine X. 15. 100390–100390. 1 indexed citations
6.
Shinkai, Masaharu, Takuhiro Sonoyama, Shinya Omoto, et al.. (2022). Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study. Vaccine. 40(32). 4328–4333. 12 indexed citations
7.
Iwata, Satoshi, et al.. (2022). Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings. Vaccine. 40(27). 3721–3726. 11 indexed citations
8.
Sonoyama, Takuhiro, Satoshi Iwata, Masaharu Shinkai, et al.. (2022). Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults. Vaccine. 41(11). 1834–1847. 2 indexed citations
9.
Bassetti, Matteo, Roger Echols, Yuko Matsunaga, et al.. (2020). 1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study. Open Forum Infectious Diseases. 7(Supplement_1). S652–S653. 2 indexed citations
10.
Wunderink, Richard G., Yuko Matsunaga, Mari Ariyasu, et al.. (2020). Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. The Lancet Infectious Diseases. 21(2). 213–225. 319 indexed citations breakdown →
11.
Katsube, Takayuki, Nao Kawaguchi, Yuko Matsunaga, et al.. (2020). 1316. Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol in Critically Ill Patients. Open Forum Infectious Diseases. 7(Supplement_1). S669–S670. 5 indexed citations
12.
Matsunaga, Yuko, Mari Ariyasu, Miki Takemura, et al.. (2020). 165. Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study. Open Forum Infectious Diseases. 7(Supplement_1). S212–S212. 3 indexed citations
13.
Bassetti, Matteo, Roger Echols, Yuko Matsunaga, et al.. (2020). Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. The Lancet Infectious Diseases. 21(2). 226–240. 540 indexed citations breakdown →
14.
Matsunaga, Yuko, Roger Echols, Mari Ariyasu, et al.. (2020). Efficacy of Cefiderocol in Severely Ill Nosocomial Pneumonia Patients in APEKS-NP Study. A2951–A2951. 1 indexed citations
15.
16.
Echols, Roger, Mari Ariyasu, & Tsutae Den Nagata. (2019). Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance. Clinical Infectious Diseases. 69(Supplement_7). S559–S564. 25 indexed citations
17.
Wunderink, Richard G., Yuko Matsunaga, Mari Ariyasu, et al.. (2019). LB4. Efficacy and Safety of Cefiderocol vs. High-Dose Meropenem in Patients with Nosocomial Pneumonia—Results of a Phase 3, Randomized, Multicenter, Double-Blind, Non-Inferiority Study. Open Forum Infectious Diseases. 6(Supplement_2). S994–S994. 13 indexed citations
18.
Portsmouth, Simon, David van Veenhuyzen, Roger Echols, et al.. (2018). Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. The Lancet Infectious Diseases. 18(12). 1319–1328. 305 indexed citations breakdown →
19.
20.
Cai, Bin, Roger Echols, Glenn Magee, et al.. (2017). Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. Open Forum Infectious Diseases. 4(3). ofx176–ofx176. 139 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tsutae Den Nagata Breakdown of academic impact, for papers by Andrew Denisuik Breakdown of academic impact, for papers by Flora Kontopidou Breakdown of academic impact, for papers by Eric Wenzler Breakdown of academic impact, for papers by Giusy Tiseo Breakdown of academic impact, for papers by Evangelos Papadomichelakis Breakdown of academic impact, for papers by Anthony Harris Breakdown of academic impact, for papers by Sofia K. Kasiakou Breakdown of academic impact, for papers by Francesca Ginocchio Breakdown of academic impact, for papers by Noriel Mariano
Rankless by CCL
2026